Cardiovascular Diseases

A Praluent boost for Sanofi, and Regeneron The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease. Praluent is an injectable prescription medicine co-developed by Sanofi and Regeneron Pharmaceuticals. It is a similar label extension as that of Amgen's drug, Repatha, which was approved in December 2017. EU grants Marketing Authorization to Zynquista The European Commission has given an OK to Sanofi’s ‘Zynquista’ (sotagliflozin) for the treatment of adults suffering from type 1 diabetes. Developed joint...